Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Rituxan Prescribers for NHL: Lymphoma Oncologists (US)

Michael Grossbard, MD, Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
Analysis of: ZymoGenetics Begins Phase 2 Clinical Trial of IL-21 in Melanoma (www.pipelinereview.com)
IL-21 is a cytokine with biological activity in regulating cytotoxic T cells and natural killer cells.   In phase I studies, some tumor reduction was observed in patients with melanoma.  The current phase II trial will be designed to assess kidvid and toxicity in patients with metastatic...
Michael Grossbard, MD, Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
Analysis of: Merck KGaA and Idera Pharmaceuticals to Collaborate on Development of TLR9 Agonists for Treatment of Cancer (www.pipelinereview.com)
TLR9 agonists have the potential to trigger the release of cytokines including interferon alfa.  IMO-2055 is a TLR9 agonist currently undergoing trials in combination with Tarceva and Avastin in patients with advanced non-small cell lung cancer and at two dose levels in a Phase IIa trial in patients...
Michael Grossbard, MD, Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
Analysis of: Infinity and MedImmune Initiate Phase 2 Trial of IPI-504 to Assess the Hsp90 Inhibitor's Potential Anti-Tumor Activity in Patients With Advanced Non-Small Cell Lung Cancer (www.pipelinereview.com)
IPI-504 is an HSP90 inhibitor with activity against cancer.  A phase I/II trial has been initiated to assess the activity of this agent in groups of patients with both EGFR mutation positive and negative tumors.  Preliminary results are available from the phase I portion of the trial...
Michael Grossbard, MD, Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
Analysis of: Avastin approved in Europe for first-line treatment of patients with advanced kidney cancer (www.pipelinereview.com)
Avastin now has been approved in Europe for the treatment of metastatic renal cell carcinoma.  However, available data leave questions as to why this agent should be favored over Sutent.
Analysis of: Targeted cancer drug poses heart risk (www.philly.com)
Pfizer's sutent cased moderate to severe cardiac toxicity in a study involving 75 patients who all had normal cardiac function at study entry. This relatively high rate of adverse events will push physicians more towards prescribing Nexavar ( Bayer/Onyx)  and Torisel (Wyeth) in patients...
Analysis of: Geron receives milestone payment from merck triggered by ind filing for telomerase cancer vaccine candidate (www.pipelinereview.com)
Geron's cancer vaccine targets telomerase which is active in growth of many cancers. Eraly clinical trials are ongoing in AML and vaccine may have role in melanoma, sarcomas, NHL and lung cancer. Main role of cancer vaccines is in minimal residual disaese or as maintenanence/consolidation therapy...
Taral Patel, MD, Oncologist
Taral Patel, MD, Oncologist
Mid Ohio Oncology Hematology Inc.
December 7, 2007
Avastin in breast cancer
Analysis of: F.D.A. Criticizes Avastin Use for Breast Cancer (www.nytimes.com)
“On face value the data look very good,” said Buzdar, who voted with the slim (5-4) majority against the drug. In the study that was the basis of Genentech’s application, Avastin appeared to slow the progress of the disease. advanced breast cancer who had already tried other drugs. He said he’s never...
Analysis of: Desmopressin Acetate (marketed as DDAVP Nasal Spray, DDAVP Rhinal Tube, DDAVP, DDVP, Minirin, and Stimate Nasal Spray) (www.fda.gov)
FDA issued warnings about severe hyponatremia and seizures associated with intranasal use of desmopressin ( DDAVP, Stimate) and cautioned against prescription for primary nocturnal enuresis- a usually large indication. DDAVP use will be now  limited to treatment of homeostasis disorders  ...
Analysis of: TopoTarget Announces Encouraging Clinical Results from Phase II Trial of Topical BACECA (R) in Combination with Retinoid for the Treatment of the Skin Cancer Basal Cell Carcinoma (www.pipelinereview.com)
Topotarget's  Baceca ( a topical form of Valproic acid) improved on the efficacy of topical retinoids in treatment of basal cell carcinoma. The main treatment of basal cell carcinoma is surgical or electrocauterization or laser. Topical therapy is limited to cases not amenable to above curative...
Analysis of: New Data Highlight That Treatment With Erbitux Allows More Resections of Preteated Patients With Metastatic Colorectal Cancer (www.pipelinereview.com)
A new French study shows that Erbitux allowed 9 of 133 pre-treated patients with colrectal cancer and liver mets to have their liver lesions become resectable. While the numbers of responding patients is small, this has huge implications since surgical resection od liver lesions may incraese survival...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next81 to 90 of 328

Analytics


Generated at 2009-01-09T13:00:20.343